Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;29(Suppl):S261-S267.
doi: 10.3350/cmh.2022.0393. Epub 2022 Dec 22.

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh  1 , Won Sohn  2 , Yong Kyun Cho  2
Affiliations
Review

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh et al. Clin Mol Hepatol. 2023 Feb.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is accepted as a counterpart to alcohol-related liver disease because it is defined as hepatic steatosis without excessive use of alcohol. However, the definition of moderate alcohol consumption, as well as whether moderate alcohol consumption is beneficial or detrimental, remains controversial. In this review, the findings of clinical studies to date with high-quality evidence regarding the effects of moderate alcohol consumption in NAFLD patients were compared and summarized.

Keywords: Alcohol related liver disease; Moderate alcohol consumption; Non alcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts to disclose.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175–1183. Erratum in: JAMA 2020;323:1619. - PubMed
    1. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) Endocr Pract. 2022;28:528–562. - PubMed
    1. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. NAFLD Consensus Consortium Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60–78. - PubMed
    1. Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28:841–850. - PMC - PubMed
    1. Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28:565–574. - PMC - PubMed